NASDAQ:IMTX Immatics (IMTX) Stock Price, News & Analysis $4.26 +0.15 (+3.65%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$4.26 0.00 (-0.12%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immatics Stock (NASDAQ:IMTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immatics alerts:Sign Up Key Stats Today's Range$4.05▼$4.2850-Day Range$3.50▼$5.3752-Week Range$3.30▼$13.77Volume205,139 shsAverage Volume650,831 shsMarket Capitalization$517.80 millionP/E RatioN/ADividend YieldN/APrice Target$16.67Consensus RatingBuy Company OverviewImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Read More… Immatics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreIMTX MarketRank™: Immatics scored higher than 50% of companies evaluated by MarketBeat, and ranked 776th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingImmatics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmatics has only been the subject of 1 research reports in the past 90 days.Read more about Immatics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immatics are expected to decrease in the coming year, from ($0.72) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is -6.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is -6.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmatics has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immatics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.94% of the float of Immatics has been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Immatics has recently decreased by 20.69%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.94% of the float of Immatics has been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Immatics has recently decreased by 20.69%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.14 News SentimentImmatics has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Immatics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for IMTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Immatics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Immatics is held by insiders.Percentage Held by Institutions64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immatics' insider trading history. Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address IMTX Stock News HeadlinesIs Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 16 at 10:11 AM | insidermonkey.comCantor Fitzgerald maintains overweight on Immatics stockApril 3, 2025 | uk.investing.comThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim Plaehn reveals how the 2025 trade war is quietly eroding dividend income — and which U.S.-focused stocks are still raising payouts.April 18, 2025 | Investors Alley (Ad)Is Immatics (IMTX) the Best German Stock to Buy According to Hedge Funds?April 2, 2025 | insidermonkey.comImmatics Full Year 2024 Earnings: Beats ExpectationsMarch 29, 2025 | finance.yahoo.comBank of America Securities Sticks to Their Buy Rating for Immatics (IMTX)March 29, 2025 | markets.businessinsider.comImmatics N.V.: Trading Below Cash, But Not Without ReasonMarch 28, 2025 | seekingalpha.comImmatics reports FY24 EPS EUR 0.14 vs (EUR 1.18) last yearMarch 27, 2025 | markets.businessinsider.comSee More Headlines IMTX Stock Analysis - Frequently Asked Questions How have IMTX shares performed this year? Immatics' stock was trading at $7.11 on January 1st, 2025. Since then, IMTX shares have decreased by 40.1% and is now trading at $4.26. View the best growth stocks for 2025 here. How were Immatics' earnings last quarter? Immatics (NASDAQ:IMTX) issued its earnings results on Thursday, March, 27th. The company reported $0.48 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.51. The business had revenue of $15.67 million for the quarter, compared to the consensus estimate of $16.16 million. Immatics had a negative trailing twelve-month return on equity of 15.90% and a negative net margin of 47.94%. Who are Immatics' major shareholders? Immatics' top institutional investors include Exchange Traded Concepts LLC (0.02%) and Intellectus Partners LLC (0.01%). How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immatics investors own include Broadcom (AVGO), Datadog (DDOG), Advanced Micro Devices (AMD), Moderna (MRNA), Cloudflare (NET) and QUALCOMM (QCOM). Company Calendar Last Earnings3/27/2025Today4/18/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMTX CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Stock Price Target$16.67 High Stock Price Target$19.00 Low Stock Price Target$15.00 Potential Upside/Downside+291.2%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.14 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,980,000.00 Net Margins-47.94% Pretax Margin-41.19% Return on Equity-15.90% Return on Assets-9.38% Debt Debt-to-Equity RatioN/A Current Ratio3.98 Quick Ratio3.98 Sales & Book Value Annual Sales$155.84 million Price / Sales3.32 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book1.48Miscellaneous Outstanding Shares121,550,000Free Float115,417,000Market Cap$517.80 million OptionableOptionable Beta0.85 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:IMTX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.